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over 4-months [mean productivity gain in favor of CRO: US$11
paid work; US$654 unpaid work]. Friends/relatives of patients
on CRO also spent less time assisting patients [mean productiv-
ity gain over 4-months in favor of CRO: US$21 paid work;
US$185 unpaid work]. Improved pain control was observed in
patients treated with CRO compared to short-acting opioids as
measured by a) proportion of patients with at least a 20%
improvement in WOMAC pain score 62.2% vs. 45.9% (p =
0.0003), b) mean HUI3 utility pain domain score at 4-months
(0.53 vs. 0.46), and c) a mean QALY gain of 0.0105 with CRO
(p = 0.1673). Mean societal cost/patient over 4 months was
US$6792 vs. US$6929 (p = 0.3345) for CRO and short-acting
opioids, respectively. CRO was both more effective and less
costly than the short-acting opioids. CONCLUSIONS: CRO
offers advantages over short-acting opioids in terms of reduced
time loss from paid and unpaid work. From the societal per-
spective, CRO was both more effective (QALYs,utilities gained
and % patients improved) and less costly than short-acting
opioid. These ﬁndings, including the impact of productivity loss
and QALYs gained should be factored into decisions about treat-
ing OA pain.
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OBJECTIVE: To demonstrate that the long term use of chon-
droitin sulfate (CS) for patients suffering osteoarthiritis (OA) is
cost-saving. METHOD: Two groups were compared, patients
treated less than 6 consecutive months (short term) with CS and
patients treated more than 6 consecutive months with CS during
2001–2002 on the IMS Disease Analyzer database. The mean
cost per patient and per month was calculated using the total
cost of treatment of the period divided by the number of patients
and the mean duration of the period (12 months for the follow
up, less or more than 6 months in the treatment period). All the
analyses were performed within a French NHS perspective.
RESULTS: We obtained two groups of respectively 56,525 and
24,732 patients treated with CS for their OA in the short and
long term groups. In the follow up period, 12 months in each
group; the mean monthly cost per patient was €9.10 for the short
term group, versus €8.18 for the long term group. This saving
of almost €11.1 per year and per patient could induce an impor-
tant saving of € 627,427.5 for the French NHS if all treated with
CS on a short term were treated on a long term. In the follow
up treatment period, patients with short term treatment cost
patients with short term treatment cost 36% more in coxibs and
42% more in NSAIDs and 190% more in analgesics (p < 0.05).
CONCLUSION: The use of CS in OA is more efﬁcient with long
term treatment, demonstrating an important cost-saving versus
short term treatment. Our economical evaluation conﬁrmed the
previous clinical demonstration of the relevance of long term use
of CS in OA.
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OBJECTIVE: To demonstrate that the long term use of chon-
droitin sulfate (CS) for patients suffering osteoarthiritis (OA)
induced less co-prescriptions. METHOD: Two groups were com-
pared, patients treated less than 6 consecutive months (short
term) with CS and patients treated more than 6 consecutive
months (long term) with CS during 2001–2002 on the IMS
Disease Analyzer database. The objective was to compare the co-
prescriptions related to OA for both groups of patient in the 12
months following the study period. In our analysis, medical con-
sultations for OA and OA prescriptions including CS, NSAIDs,
analgesics, coxibs and gastro-protective agents were taken into
account. RESULTS: We obtained two groups of respectively
56,525 and 24,732 patients treated with CS for their OA in the
short and long term groups. In the follow up period, patients
with short term and long term treatment had respectively in term
of co-prescriptions 37% vs. 38% of NSAIDs, 75% vs. 71% of
analgesics and 21% in both groups of coxibs. But the mean
length of treatment’s days by co-prescriptions were respectively
of 40 vs. 37 for NSAIDs, 82 vs. 68 for analgesics and 79 vs. 59
for coxibs (p < 0.01). CONCLUSION: The results of this survey
allowed us to conclude that in addition to the fact that the use
of CS in OA is more efﬁcient with long term treatment, it was
also safer compared to short term treatment. A long term treat-
ment reduces the length of treatment of each co-prescriptions.
The saving of 20 days of coxibs treatments, 3 days of NSAIDs
and 14 days of analgesics demonstrated that the long term use
of CS conﬁrmed that in real life the efﬁciency and the safety
proﬁle made it a safe approach taking into consideration the high
risk proﬁle (Gastro-intestinal, cardiovascular, etc.) of the other
OA symptomatic treatments.
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OBJECTIVE: To evaluate upper GI (UGI) events, use of GI med-
ications, and health care costs among arthritis patients in a
managed care setting. METHODS: Commercial claims data for
three million health maintenance (HMO) and preferred provider
organization (PPO) members in Southeast U.S. were used to
identify new users of COX-2s and NSAIDs in 2002. Patients had
≥1 arthritis-related claim followed by an index claim for COX-
2 (rofecoxib, valdecoxib or celecoxib) or NSAID (ibuprofen,
naproxen, diclofenac, and nabumetone) and were continuously
enrolled for ≥ one year pre- and post-index date. Patients dis-
pensed either a COX-2 or NSAID during one year pre-index and
patients with claims for both COX-2s and NSAIDs were
excluded. Multiple logistic regression was used to model UGI
events (ulcers and bleeds) and GI medication use (proton pump
inhibitors and H2-antagonists), and a log transform model was
used for total health care costs (medical and prescription) at 1
year controlling for age, gender, health status, medication per-
sistence, and baseline utilization. RESULTS: In total, 3449
arthritis patients were included: 47% COX-2 (26% rofecoxib,
15% celecoxib, 7% valdecoxib) and 53% NSAID. Patients in
the COX-2 group were signiﬁcantly older, taking more medica-
tions and more persistent, more likely to be female or belong to
a PPO, and had more comorbidities, GI events, and higher costs
